Cereno Scientific announced that Don de Bethizy has been engaged as Senior Advisor to the Executive Management and Board of Directors of Cereno Scientific, to support the company in reaching its strategic growth objectives. J. Donald (Don) de Bethizy,PhD has more than 30 years of experience in managing and financing life science-related technologies and has played a key role in building and advising several life sciences companies. Don de Bethizy advised the CEO and board of NDA Group AB one of the world's leading private biotechnology regulatory consulting firms until its sale to SSI Strategy in 2023.

In 2017, Don facilitated the management buyout of Albumedix Ltd. from Novozymes A/S and the subsequent sale of Albumedix Ltd. to Sartorius for 415 MGBP in late 2022. Currently, Don de Bethizy is Vice Chair of the board of argenx NV a global commercial immunology company headquartered in Gent, Belgium with 2023 sales of 1.2 BUSD of its first drug Vyvgart in the rare autoimmune disease myasthenia gravis. In 2014, in his role as Chief Executive Officer of the Danish biotech Santaris Pharma A/S, he led the sale of the company to Roche for 450 MUSD.

He co-founded Targacept Inc. and served as its President and Chief Executive Officer for 15 years. Don de Bethizy led Targacept's private and US Nasdaq public financings totaling approximately 330 MUSD, including the Company's Initial Public Offering (IPO) in April 2006. Don de Bethizy holds a B.S. in Biology from the University of Maryland and an M.S. and PhD in Toxicology from Utah State University.

He is currently President of White City Consulting ApS (Denmark), a Director at Lophora ApS (Denmark) and Proterris Inc. (USA). He is a U.S. citizen and resident of Denmark.